NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9479	Companies
185510	Keywords
117899	Articles
99364	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 08/08/2024 at 12:35, 1 year 3 months ago

NanoViricides Updates Clinical Program and Strategy

NV-387 Clinical Trials RSV Treatment Antiviral Nanomedicines Broad-spectrum Antiviral
BRIEF

published on 08/08/2024 at 12:35, 1 year 3 months ago

NanoViricides met à jour son programme clinique et sa stratégie

NV-387 Essais Cliniques Antiviral À Large Spectre Nanomédicaments Antiviraux Traitement Du VRS
PRESS RELEASE

published on 08/08/2024 at 12:30, 1 year 3 months ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides provides update on clinical program & strategy for novel antiviral drug NV-387, targeting Influenza, COVID, RSV & more. Broad-spectrum potential discussed

NanoViricides NV-387 Clinical Program Antiviral Drug Broad-spectrum
BRIEF

published on 08/01/2024 at 12:35, 1 year 4 months ago

NanoViricides' Broad Spectrum Technology Promises New Approach in Viral Therapy

NanoViricides NV-387 Clinical Trials Antiviral Therapy Market Potential
BRIEF

published on 08/01/2024 at 12:35, 1 year 4 months ago

La technologie à large spectre des nanoviricides promet une nouvelle approche en matière de thérapie virale

NanoViricides NV-387 Essais Cliniques Potentiel De Marché Thérapie Antivirale
PRESS RELEASE

published on 08/01/2024 at 12:30, 1 year 4 months ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
NanoViricides, Inc., reports on independent research highlighting NV-387's broad-spectrum action in viral therapy, potentially revolutionizing antiviral treatment strategies

NV-387 NanoViricides Inc. Antiviral Nanomedicines Broad-spectrum Action Viral Therapy
BRIEF

published on 07/24/2024 at 12:35, 1 year 4 months ago

NanoViricides Highlights NV-387's Potential Against COVID-19

COVID-19 NanoViricides NV-387 Clinical Trials Antiviral
BRIEF

published on 07/24/2024 at 12:35, 1 year 4 months ago

Les nanoviricides mettent en évidence le potentiel du NV-387 contre le COVID-19

NanoViricides NV-387 Essais Cliniques COVID 19 Antiviral
PRESS RELEASE

published on 07/24/2024 at 12:30, 1 year 4 months ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
NanoViricides, Inc. showcases strong safety and effectiveness of lead drug NV-387 against coronaviruses, potentially filling the gap in COVID treatments. Seeking collaborations for regulatory approvals

NanoViricides NV-387 Drug Development Coronaviruses COVID Treatments
BRIEF

published on 07/11/2024 at 12:35, 1 year 4 months ago

NanoViricides Plans Next Phase of Clinical Trials for Broad-Spectrum Antiviral NV-387

NanoViricides NV-387 Clinical Trials Antiviral Drug Broad-spectrum

Accesswire

Published on 12/05/2025 at 17:15, 52 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 7 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 2 hours 7 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 2 hours 22 minutes ago

Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme
Published on 12/05/2025 at 15:45, 2 hours 22 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:51, 15 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 20 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 6 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 41 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 57 minutes ago

Reorganization of the Eckert & Ziegler Executive Board

Les Echos

Published on 12/05/2025 at 17:18, 49 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 49 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 2 hours 56 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 2 hours 56 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 4 hours 8 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE